Catalyst
Slingshot members are tracking this event:
Achillion Initiates Phase 1 Study of ACH-4471, First Orally-Administered Small Molecule Complement Factor D Inhibitor
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| ACHN |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Feb 11, 2016
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Phase 1 Study, Ach-4471, Small Molecule Complement Factor D Inhibitor
